Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2011. The report details a specific share repurchase transaction executed on May 10, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Repurchased: 525,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,310.50 pence per share; lowest price paid was 1,300.00 pence per share.
- Treasury Shares Held: 493,224,284 shares (representing 8.72% of total issued share capital and 9.55% of total voting rights).
- Shares in Issue: 5,164,056,296 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 525,000 repurchased shares. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,164,056,296) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of Treasury shares held (8.72% of issued capital) to assess potential dilution or buyback capacity.
- Review the specific price range (1,300.00 to 1,310.50 pence) paid for the repurchased shares to evaluate capital allocation efficiency.